ASSET PURCHASE AND LICENSE AGREEMENT BY AND BETWEEN ALKERMES, INC. AND CORREGIDOR THERAPEUTICS, INC. DECEMBER 27, 2010Asset Purchase and License Agreement • August 26th, 2014 • Civitas Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This Asset Purchase and License Agreement (the “Agreement”) is made effective as of the 27th day of December 2010 (the “Effective Date”) by and between Alkermes, Inc., a Pennsylvania corporation having a principal place of business at 852 Winter Street, Waltham, Massachusetts 02451 (“Alkermes”), and Corregidor Therapeutics, Inc., a Delaware corporation with its principal place of business located at 384 Powder Mill Road, Concord, MA 01742 (“Corregidor”). Alkermes and Corregidor are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 26th, 2014 • Civitas Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), made as of this 12th day of January 2014, is entered into by Civitas Therapeutics, Inc., a Delaware corporation with its principal place of business at 190 Everett Avenue Chelsea, MA 02150 (the “Company”), and Mark Iwicki, residing at [—] (the “Executive”).
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 26th, 2014 • Civitas Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
This AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (the “Agreement”), made as of this 22 day of August, 2014, is entered into by Civitas Therapeutics, Inc., a Delaware corporation with its principal place of business at 190 Everett Avenue, Chelsea, MA 02150 (the “Company”), and Rick Batycky (the “Executive”).
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • August 26th, 2014 • Civitas Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts
CIVITAS THERAPEUTICS, INC. THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTRights Agreement • August 26th, 2014 • Civitas Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT is made as of the 22nd day of August, 2014, by and among Civitas Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”.
